TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02447874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine
Description: Arginine will be dispensed intravenously (in the vein) in the standard dose of arginine as 100 mg/kg three times a day for seven days or until discharge.~* Loading dose: 200 mg/kg once~* Continuous IV: 300 mg/kg/24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine
Description: Arginine will be dispensed intravenously (in the vein) in the standard dose of arginine as 100 mg/kg three times a day for seven days or until discharge.~* Loading dose: 200 mg/kg once~* Continuous IV: 300 mg/kg/24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine (Loading)
Description: Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) at each specified group dose once, followed by a standard dose of 100mg/kg every 8 hours until discharge or for a total of 21 doses of arginine, whichever comes first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine (Loading)
Description: Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) at each specified group dose once, followed by a standard dose of 100mg/kg every 8 hours until discharge or for a total of 21 doses of arginine, whichever comes first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine (Loading)
Description: Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) at each specified group dose once, followed by a standard dose of 100mg/kg every 8 hours until discharge or for a total of 21 doses of arginine, whichever comes first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine (Loading)
Description: Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) at each specified group dose once, followed by a standard dose of 100mg/kg every 8 hours until discharge or for a total of 21 doses of arginine, whichever comes first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine (Loading)
Description: Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) at each specified group dose once, followed by a standard dose of 100mg/kg every 8 hours until discharge or for a total of 21 doses of arginine, whichever comes first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine (Continuous)
Description: Arginine will be dispensed intravenously (in the vein) as a continuous IV infusion of 300 mg/kg/24hr
Study: NCT02152163

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Ibuprofen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03129373

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryogenic treatment of warts
Description: Treatment of common and plantar wart by cryotherapy treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryogenic treatment of warts
Description: Treatment of common and plantar wart by cryotherapy treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryogenic treatment of warts
Description: Treatment of common and plantar wart by cryotherapy treatment.
Study: NCT01065610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05191550

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality brain tumor simulation
Description: Task: Complete removal of a simulated tumour - distinguishable by colour and haptic properties - with minimal bleeding and damage to surrounding healthy brain using two surgical instruments (Cavitron Ultrasonic Aspirator and Bipolar pincers) of the NeuroVR (CAE Healthcare) surgical simulator.~Intervention: A single 28-minute simulation session, including six virtual subpial tumour resection attempts. Five simple practice scenarios (3 minutes per task) and one complex realistic scenario (13 minutes). Pre- and post-questionnaires to obtain participant demographics and assess face and content validity of the simulated tasks.
Study: NCT00392665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Given intravenously on day one of each 3 week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib
Description: Given orally once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib
Description: Given orally once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulindac
Description: Given orally twice a day
Study: NCT00901745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Description: Infusion of up to 30picmol/ml angiotensin II will be infused and respondent vasoconstriction assessed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin II
Description: Infusion of up to 30picmol/ml angiotensin II will be infused and respondent vasoconstriction assessed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Noradrenaline infusion
Description: Infusion of up to 480 picomol/ml of noradrenaline will be infused.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Noradrenaline infusion
Description: Infusion of up to 480 picomol/ml of noradrenaline will be infused.
Study: NCT02604732

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic inguinal hernia repair without perioperative Aspirin
Description: Patients undergoing laparoscopic inguinal hernia repair will stop Aspirin 5-7 days before the surgery
Study: NCT04364321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam 0.5 MG
Description: Clonazepam 0.02 mg/kg only one dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam Tablets
Description: Diazepam 0.3 mg/kg every 8 hours for 3 doses. (24 hr)
Study: NCT02259244

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight reduction program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight reduction program
Study: NCT01725958

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplement and protein shakes
Study: NCT01133470

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexofenadine HCl + Pseudoephedrine HCl
Description: Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's KLaboratories Limited

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl + Pseudoephedrine HCl
Description: Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's KLaboratories Limited
Study: NCT04215822

Intervention type: DIAGNOSTIC_TEST
Intervention: Cytogenetic analysis (FISH) for EZH2 gene deletion. -Real time PCR for PHF 19 gene expression.
Description: Cytogenetic analysis (FISH) for EZH2 gene deletion. -Real time PCR for PHF 19 gene expression.
Study: NCT00789230

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: primary suture closure
Description: primary suture closure of hernia

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mesh enforced closure
Description: mesh enforced closure of hernia
Study: NCT02195193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated care
Description: an integrated care model for ACS and depression delivered by a collaborative team composed of cardiologists/internists and nurses in the same rural county hospital. The collaborative team will be able to provide medical services for the diagnosis and treatment at acute phase of ACS during hospitalization, ACS secondary prevention therapies at and after discharge, and screening and treatment of depression depressive symptom during hospitalization and after discharge. The core of the interventions includes: depressidepressive symptomon screening and classification, individual counseling and medical treatment of depression, group counseling and health education, and follow-up for ACS and depression treatments compliance, IT- system- assisting theassisted management and necessary referral.
Study: NCT01174225

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexi T 380(+) IUD
Description: The intrauterine device is placed in the uterus immediately post-abortion. Participant is counseled that she may leave the device in for up to five years.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nova T IUD
Description: The intrauterine device is placed in the uterus immediately post-abortion. Participant is counseled that she may leave the device in for up to five years.
Study: NCT02477202

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirena® intra-uterine device (IUD)
Description: In this study, a Mirena® IUD will be inserted into volunteers scheduled for a risk-reducing salpingo-oophorectomy (RRSO) or risk-reducing salpingectomy (RRS) at Memorial Sloan Kettering Cancer Center (MSK). Alternatively, women with a Mirena® IUD already in place and who will be scheduled for an RRSO or RRS at MSK can also participate. We are seeking 14 evaluable participants. FTF tissue (and ovarian inclusion cyst tissue, when available) collected at the time of risk-reducing salpingectomy (RRS) will be tested by immunochemistry staining for Ki67 (a protein that is significantly increased when cells are preparing for division).
Study: NCT01648582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Administered SC per dosing titration schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylureas
Description: Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylureas
Description: Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfonylureas
Description: Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.
Study: NCT01841151

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WM training
Study: NCT04460430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib + endocrine therapy
Description: Neratinib plus Fulvestrant, Exemestane or Tamoxifen
Study: NCT01225354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium hydroxylapatite
Description: Subjects will be treated to full correction at visit 1 and, if needed, a touch-up injection at 2 weeks.
Study: NCT00326820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate sodium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zoledronic acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolendronic Acid
Description: Zoledronic acid 4 mg by intravenous infusion every 4 weeks.
Study: NCT04222985

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV 2 Formulation 1
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV 2 Formulation 1
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV 2 Formulation 1
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV 2 Formulation 2
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV 2 Formulation 2
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV 2 Formulation 2
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV 2 Formulation 3
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV 2 Formulation 3
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV 2 Formulation 3
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV 2 Formulation 3
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV 2 Formulation 3
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV 2 Formulation 3
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV 2 Formulation 3
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV 2 Formulation 3
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV 2 Formulation 3
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV 2 Formulation 4
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV 2 Formulation 4
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV 2 Formulation 4
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV 2 Formulation 5
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV 2 Formulation 5
Description: Route of administration: Intramuscular
Study: NCT01092156

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Education on Infant-led latching
Study: NCT05778539

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral retinacular release
Description: During the implantation of a total knee arthroplasty a lateral retinacular release is performed in the intervention group
Study: NCT03097263

Intervention type: OTHER
Intervention: Physical Rehabilitation program
Study: NCT02540304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reducing the Risk
Description: Safer Sex is a clinic-based intervention intended to reduce the incidence of STIs and increase condom use among high-risk sexually active female adolescents and delivered in face-to-face individualized sessions by a female health educator. Reducing the Risk is a sexuality-education curriculum, most often delivered in a school setting that provides instruction and practice in the social skills needed to put into action what students learn about preventing pregnancy and reducing unsafe behavior in future high-risk situations. ¡Cuidate! is adapted from the Be Proud! Be Responsible! curriculum and culturally tailored for Latino youth. It aims to reduce HIV risk and unintended pregnancies by affecting sexual behaviors such as intercourse, number of partners, and condom use.
Study: NCT02452411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment approach supported by virtual reality and positive psychology strategies.
Description: The CBT program consists of 6 weekly sessions (and 2 additional ones depending on the patient's needs) with the following main therapeutic components: educational component, exposure/processing of the stressful event with VR (EMMA's World) and relapse prevention. EMMA's World is an open and flexible VR system that uses symbols (e.g., 3D-objects, pictures, sounds) to reflect and evoke the negative emotions associated to the stressful event. Also, several strategies from Positive Psychology (e.g., My best virtues or strengths exercise) and others based on Neimeyer's (2000) suggestions for pathological grief (e.g., projection letter to the future) are also included in the protocol.
Study: NCT01042665

Intervention type: DRUG
Intervention: latanoprost 0.005%
Description: Active comparator

Intervention type: DRUG
Intervention: latanoprost 0.005%
Description: Active comparator

Intervention type: DRUG
Intervention: Placebo
Description: Placebo comparator

Intervention type: DRUG
Intervention: Placebo
Description: Placebo comparator
Study: NCT00882505

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: Subject will receive vitamin d supplements

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject will receive a placebo.
Study: NCT04546334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical treatment
Description: routine medical treatment of post herpetic neuralgia as controls (Pregabalin, acyclovir, and paracetamol)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical treatment
Description: routine medical treatment of post herpetic neuralgia as controls (Pregabalin, acyclovir, and paracetamol)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical treatment
Description: routine medical treatment of post herpetic neuralgia as controls (Pregabalin, acyclovir, and paracetamol)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real Erector Spinae block
Description: Ultrasound guided Erector spinae plane block with injection of local anesthetic bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real Erector Spinae block with magnesium sulphate
Description: Ultrasound guided Erector spinae plane block with injection of local anesthetic bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose with the addition of MgSO4 (equivalent to 100 mg))

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Erector Spinae block
Description: Ultrasound guided Erector spinae plane block with injection ofnormal saline
Study: NCT04289948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phage
Description: The studies will be undertaken using a cocktail of at least 2-3 anti-staphylococcal phages produced by Intralytix Inc, Baltimore, Maryland, USA. The phages will be included in a gel designed for application directly to the wound surface and packaged in 5 ml single use tubes.
Study: NCT04222985

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV 2 Formulation 5
Description: Route of administration: Intramuscular
Study: NCT04289948

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phage
Description: The studies will be undertaken using a cocktail of at least 2-3 anti-staphylococcal phages produced by Intralytix Inc, Baltimore, Maryland, USA. The phages will be included in a gel designed for application directly to the wound surface and packaged in 5 ml single use tubes.
Study: NCT02818803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Propolis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Miconazole
Study: NCT02472093

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercises treatment
Description: Includes different types of exercises: low-impact to moderate aerobic training; walking fast in a circle, alternating with periods of going up and down the stairs (3 steps for 10 minutes) for a total of 20 consecutive minutes; posture exercises for the back and proprioceptive exercises for the trunk in the supine position to improve axial stability, including diaphragmatic breathing. The heart rate was monitored through the use of a heart rate monitor, which allowed not to exceed the threshold.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perceptive Rehabilitation Treatment
Description: therapeutic system that is based on the interaction between the patient's back or painful area and a support surface, composed of small latex cones with various dimensions (height: 3-8 cm; base diameter: 2-4 cm) and elasticities. The inferior bases of these cones are applied to a rigid wood surface using elastic strips.
Study: NCT02404701

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk thistle
Description: Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Turmeric
Description: Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aloe vera
Description: Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
Study: NCT01415232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonosite S-Nerve® US system (SonoSite, Bothell,WA)
Description: Ultrasound to measure depth to the epidural space in morbidly obese parturients